menu
    • menu
    PHARMACOMPASS
    PHARMACOMPASS

    Grow Your Pharma Business Digitally
    X
    Market Place Market Place
    Sourcing support Sourcing Support
    API / FDF
    Excipients
    Services
    Developments
    News
    Market Intel
    #Phispers
    #SpeakPharma
    #LearnMore

    NEWS

    DRUGS & DEVELOPMENTS

    MARKET INTEL by PharmaCompass

    Polfa Tarchomin is a leading Polish pharmaceutical company with 200 year tradition in manufacture and sale of pharmaceutical products.

    Macleods Pharma`s Generics Canagliflozin Receives Tentative Approval in US

    FDA

    Indoc`s Biologic Canagliflozin;Metformin HCL Receives Tentative Approval in US

    FDA

    Lupin`s Generic Canagliflozin, Metformin Hydrochloride Receives Approval in the U.S.

    FDA

    USFDA approves Zydus Canagliflozin and Metformin Hydrochloride tablets

    HEALTH ET

    Zydus` Generic Canagliflozin, Metformin Hydrochloride Receives Approval in the U.S.

    FDA

    Zydus receives USFDA tentative approval for Canagliflozin Tablet

    BUSINESS STANDARD

    Zydus` Generic Canagliflozin Receives Approval in the U.S.

    FDA

    Laurus Labs` Generic Canagliflozin Receives Approval in the U.S.

    FDA

    Heart failure symptoms improved with a type 2 diabetes medicine

    NEWSROOM

    Acute heart failure patients benefit with type 2 diabetes medication

    NEWSROOM

    J&J looks to toss its SGLT2 hat in the ring for two types of heart failure

    ENDPTS

    KidneyIntelX™ Enables Monitoring of SGLT2 Inhibitor Therapy Response

    GLOBENEWSWIRE

    Canagliflozin (TA-7284) has been approved in Taiwan For Diabetic Nephropathy

    PRESS RELEASE

    Sandoz`s Generic Canagliflozin;Metformin HCL Receives Tentative Approval in US

    FDA

    New Study Offers Hope for Patients with Diabetes and Advanced Kidney Disease

    PRNEWSWIRE

    AstraZeneca`s Farxiga cuts kidney disease risks by 39% in trial

    FIERCE PHARMA

    FDA pulls J&J`s Invokana boxed amputation risk warning

    FIERCE PHARMA

    FDA: Amputation risk boxed warning removed from canagliflozin

    HEALIO

    Dr Reddys Lab`s Generic Canagliflozin;Metformin HCL Receives T. Approval in US

    FDA

    Europe extends Invokana indication to cover diabeticKD in type 2 diabetes

    PHARMAFILE

    Napp Pharmaceuticals Announces European Commission Approval of Invokana®

    BUSINESSWIRE

    Napp Announces European Commission Approval of Invokana® (canagliflozin)

    BUSINESSWIRE

    CHMP Issues Positive Opinion to Extend Invokana® (Canagliflozin)

    YAHOO

    Janssen`s INVOKANA Gets Boost Over Competitors with FDA Approval

    PR NEWSWIRE

    CREDENCE Study Shows the Efficacy and Safety Profiles INVOKANA® (canagliflozin)

    PR NEWSWIRE

    J&J taps kidney specialist Vifor for Invokana marketing help

    FIERCEP PHARMA

    Mundipharma: Swissmedic reviewing licence extension

    BUSINESSWIRE

    J&J’s Invokana gets lifeline with new kidney disease approval

    PMLIVE

    Catabasis Pharma Announces the Phase 3 PolarisDMD Trial of Edasalonexent

    BIOSPACE

    Novo`s Ozempic tops Invokana, Victoza in double head-to-head win

    FIERCE PHARMA

    Novo`s Ozempic tops Invokana, Victoza in double head-to-head win

    FIERCE PHARMA

    AstraZeneca aims to pump up Farxiga marketing after cardio outcomes study

    FIERCEPHARMA

    EMA accepts license extension submission for Invokana and Vokanamet

    PHARMA TIMES

    Mundipharma Announces the Licence Extension Sub for Invokana® Vokanamet®

    BUSINESSWIRE

    Glenmark launches Remogliflozin combo in India; GeneCentric buys Select Immuno

    ENDPTS

    Boehringer posts solid first half as business revamp beds in

    PMLIVE

    Farxiga follows rival Zynquista to FDA rejection in Type 1 diabetes

    FIERCE PHARMA

    FDA fast-tracks BI, Lilly`s Jardiance in chronic heart failure

    FIERCE PHARMA

    J&J`s struggling Invokana slashes heart, kidney risks in latest trial win

    FIERCE PHARMA

    AstraZeneca`s Farxiga scores in kidney outcomes study, cutting risks 47%

    FIERCE PHARMA

    J&J’s Invokana closes on diabetic kidney disease approval

    PHARMAPHORUM

    J&J’s Invokana closes on diabetic kidney disease approval

    PHARMAPHORUM

    Researchers highlight risk of flesh-eating bacteria for SGLT2s

    FIERCE PHARMA

    Janssen`s Invokana combo smashes primary & secondary endpoints in CKD

    PHARMAFILE

    Data show J&J’s Invokana may slow or prevent CKD in diabetes patients

    PHARMA TIMES

    J&J submits sNDA for Invokana after premature end to clinical trial

    PHARMA TIMES

    FDA Confirms Paragraph IV Patent Challenge of Invokamet-XR 205879 (Canagliflozin and Metformin Hydrochloride) Extended-release Tablets

    FDA

    Diabetes drugs in SGLT2 inhibitor class linked to pancreatitis genital infection

    PHARMABIZ

    AZ`s Farxiga won its EU nod in Type 1. How will it fare at FDA?

    FIERCE PHARMA

    J&J pays $500M in cash to grab rights to a new star cancer drug at argenx

    ENDPTS

    Johnson & Johnson backs new Invokana CV nod with series of awareness tweets

    FIERCE PHARMA

    AstraZeneca`s Farxiga lowers hospitalizations for heart failure by 17%

    FIERCE PHARMA

    Johnson & Johnson bags long-awaited CV nod for diabetes drug Invokana

    FIERCE PHARMA

    FDA Experts May Reconsider Diabetes Drug Safety Rules

    FORBES

    Janssen`s Invokana (canagliflozin) Receives Approval in Europe

    EMA

    Janssen-Cilag`s Invokana (canagliflozin) Receives Approval in Europe

    EMA

    Johnson & Johnson Completes Divestiture of LifeScan to Platinum Equity

    PRESS RELEASE

    How One Class Of Diabetes Meds May Lead To Flesh-Eating Genital Infections

    FORBES

    EMA issues positive opinion to Janssen’s INVOKANA and VOKANAMET

    BIOSPECTRUM

    PDL BioPharma Acquires Depomed`s Remaining 50% Interest in Royalties

    PR NEWSWIRE

    Copyright © 2025 LePro PharmaCompass OPC Private Limited, All rights reserved.